Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome

We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent (18)F-Fluorodeoxyglucose ([(18)F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month th...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgard, Caroline, Rosar, Florian, Khreish, Fadi, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Interesting Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947295/
https://www.ncbi.nlm.nih.gov/pubmed/35328232
http://dx.doi.org/10.3390/diagnostics12030680
_version_ 1784674405809389568
author Burgard, Caroline
Rosar, Florian
Khreish, Fadi
Ezziddin, Samer
author_facet Burgard, Caroline
Rosar, Florian
Khreish, Fadi
Ezziddin, Samer
author_sort Burgard, Caroline
collection PubMed
description We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent (18)F-Fluorodeoxyglucose ([(18)F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month therapy with midostaurin, an established tyrosine kinase inhibitor. Post-therapeutic [(18)F]FDG PET/CT showed decreased multifocal tracer uptake in the known lesions in the gastrointestinal tract, which was consistent with relief of the patient’s symptoms and decrease in serum tryptase level. [(18)F]FDG PET/CT may thus be considered a potential method for monitoring the outcome of midostaurin therapy in systemic mastocytosis.
format Online
Article
Text
id pubmed-8947295
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89472952022-03-25 Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome Burgard, Caroline Rosar, Florian Khreish, Fadi Ezziddin, Samer Diagnostics (Basel) Interesting Images We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent (18)F-Fluorodeoxyglucose ([(18)F]FDG) positron-emission tomography/computed tomography (PET/CT) pre- and post-6-month therapy with midostaurin, an established tyrosine kinase inhibitor. Post-therapeutic [(18)F]FDG PET/CT showed decreased multifocal tracer uptake in the known lesions in the gastrointestinal tract, which was consistent with relief of the patient’s symptoms and decrease in serum tryptase level. [(18)F]FDG PET/CT may thus be considered a potential method for monitoring the outcome of midostaurin therapy in systemic mastocytosis. MDPI 2022-03-10 /pmc/articles/PMC8947295/ /pubmed/35328232 http://dx.doi.org/10.3390/diagnostics12030680 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Interesting Images
Burgard, Caroline
Rosar, Florian
Khreish, Fadi
Ezziddin, Samer
Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
title Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
title_full Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
title_fullStr Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
title_full_unstemmed Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
title_short Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
title_sort systemic mastocytosis treatment with midostaurin: [(18)f]fdg pet/ct as a potential monitoring tool for therapy outcome
topic Interesting Images
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947295/
https://www.ncbi.nlm.nih.gov/pubmed/35328232
http://dx.doi.org/10.3390/diagnostics12030680
work_keys_str_mv AT burgardcaroline systemicmastocytosistreatmentwithmidostaurin18ffdgpetctasapotentialmonitoringtoolfortherapyoutcome
AT rosarflorian systemicmastocytosistreatmentwithmidostaurin18ffdgpetctasapotentialmonitoringtoolfortherapyoutcome
AT khreishfadi systemicmastocytosistreatmentwithmidostaurin18ffdgpetctasapotentialmonitoringtoolfortherapyoutcome
AT ezziddinsamer systemicmastocytosistreatmentwithmidostaurin18ffdgpetctasapotentialmonitoringtoolfortherapyoutcome

Ejemplares similares